There are a number of factors which determine which drugs are available in Canada for treating multiple myeloma. First, to be used in Canada, the drug must be approved by Health Canada as safe and effective. Second, in order that people can access the medication, there must be funding by the provincial health insurance programs. Myeloma drugs currently approved for use in Canada include melphalan, cyclophosphamide, bisphosphonates (pamidronate, zoledronic acid and clodronate), Velcade (bortezomib) for front-line combination therapy or second-line therapy and lenalidomide (Revlimid). Thalidomide can be obtained through special access programs.
ASCT Eligible Patients:
study, an Ortho Biotech trial of melphalan, prednisone and Velcade (bortezomib) and the Celgene MM020 international trial (comparing three regimens: lenalidomide + weekly dexamethasone until progression, lenalidomide + weekly dexamethasone for 18 months, vs. MP + thalidomide).